arrow
A

Adam DuVall

university of utah
H指数:13
被引数:622

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Reduced-dose pegylated asparaginase reliably achieves therapeutic levels in adult patients with acute lymphoblastic leukaemia and lymphoblastic lymphoma

减量聚乙二醇化天冬酰胺酶在成人急性淋巴细胞白血病和淋巴母细胞淋巴瘤患者中可靠地达到治疗水平

2026-10-180
OAAI
Targeting CD38 with bispecific antibody XmAb 18968 in patients with relapsed/refractory acute myeloid leukemia and T-cell acute lymphoblastic leukemia

靶向CD38的双特异性抗体XmAb 18968在复发/难治性急性髓系白血病和T细胞急性淋巴细胞白血病患者中的应用

Leukemia
IF13.4
2026-09-140
PRE
Choice of hypomethylating agent for newly diagnosed TP53-mutant acute myeloid Leukemia: a COMMAND registry study
Leukemia
IF13.4
2026-08-310
PRE
American Society of Hematology 2026 guidelines for frontline management of acute lymphoblastic leukemia in adolescents and young adults
2026-07-040
OA
Predictors of complete molecular response and impact of allogeneic hematopoietic stem cell transplantation on outcome in patients with Philadelphia chromosome positive acute lymphoblastic leukemia (ALL): results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

费城染色体阳性急性淋巴细胞白血病(ALL)患者完全分子缓解的预测因素及异基因造血干细胞移植对预后的影响:来自骨髓恶性肿瘤和肿瘤疾病联盟(COMMAND)的结果

2026-06-071
PRE
Second Line CD19 CAR-T vs Platinum Salvage and Autologous Stem Cell Transplant for Primary Mediastinal B-Cell Lymphoma

二线CD19 CAR-T治疗与铂类挽救疗法及自体干细胞移植治疗原发纵隔B细胞淋巴瘤的比较

2026-01-010
OA
Social Genomic Mechanisms of Health Disparities Among Adolescent/Young Adult Survivors of Hodgkin and Non-Hodgkin Lymphoma: ECOG-ACRIN E

健康不平等的社会基因组机制:霍奇金和非霍奇金淋巴瘤青少年/青年成年幸存者研究:ECOG-ACRIN E

2025-11-010
PRE
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post-revumenib therapies

复发/难治性急性白血病接受revumenib治疗的患者结局,重点关注revumenib治疗后的疗法

2025-10-260
OAAI
Outcomes of older patients with TP53-mutated myeloid neoplasms

TP53突变髓系肿瘤老年患者的结局

2025-10-070
OA
Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults

成人TP53突变急性淋巴细胞白血病的临床与分子特征

2025-08-140
OAAI
Incorporation of patient-reported outcomes in pediatric cancer clinical trials: design, implementation, and dissemination

将患者报告结局纳入儿科癌症临床试验:设计、实施与传播

2025-03-310
PRE
Prognostic Impact of Chromosome 7 Losses in High-Grade TP53 Mutated Myeloid Neoplasms

染色体7丢失对TP53突变的高级别髓系肿瘤的预后影响

2025-03-010
PRE
Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1-familial platelet disorder

靶向CD74信号轴可抑制炎症并挽救RUNX1-家族性血小板异常中的造血缺陷

2025-01-080
PRE
Outcomes of BCR::ABL1-like B-Lineage Acute Lymphoblastic Leukemia in the Era of Novel Therapies

BCR::ABL1-like B系急性淋巴细胞白血病在新型疗法时代的结局

BLOOD
IF23.1
2024-11-050
PRE
Interim Results of a Phase II Study Investigating Dasatinib and Inotuzumab Ozogamicin-Based Induction for Newly-Diagnosed Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph plus ALL)

一项关于达沙替尼和伊诺妥单奥唑米星为基础诱导治疗新诊断费城染色体阳性急性淋巴细胞白血病(Ph plus ALL)的II期研究中期结果

BLOOD
IF23.1
2024-11-050
PRE